525-patient trial intends to assess ‘complement activation’ during HD in patients with end stage renal failure

VLA1553 had a high seroresponse rate among participants 28 days after receiving a single administration

The pharmaceutical company Merck has sued the US government over negotiated pricing of drugs for the Medicare programme […]

Five general practices in England have secured large reductions to the service charges for their premises after reaching […]

The health inequities facing women and gender diverse people are well known.1 Sex differences exist in both prevalence […]

Launer’s eulogy to the public library jogged deep memories.1 My parents left a small town in northern India, […]

In the call for the NHS to improve data on antenatal mental health screening, Trudi Seneviratne says, “It’s […]

The treatment candidate, known as MDI-26478, is a positive allosteric modulator of the AMPA receptor

Objective response rate and complete response rates were encouraging for both treatments